The US FDA approved KBP-7072 to enter Phase I clinical study in April 2015.

Jinan, China and Princeton, New Jersey, USA (4/2/2015) KBP BioSciences, a clinical stage biotech company with operations in China, US, and Singapore, today announced that the US FDA approved Initial New Drug Application (IND) for its experimental drug KBP-7072 for the potential treatment of serious bacterial infections.

KBP-7072 is a next generation tetracycline targeting bacterial resistance that has become global epidemic. KBP-7072 was shown in In Vitro studies to be very effective against a broad spectrum of bacteria, including resistant strains, MRSA, MRSE, PRSP, VRE, anaerobic strains, among others. “Bacterial resistance has grown significantly across the globe and is threatening human society. For the tens of thousands patients who lost the battle against resistant microbes, this drug could be a life saver.” Said Dr. Zhenghua Huang, President of KBP BioSciences. “We are moving KBP-7072 along the development path as quickly as we can to meet global demands.”

Testing of KBP-7072 in healthy volunteers will soon start in the United States. KBP has established its global clinical research center in the state of New Jersey to manage its growing portfolio of clinical stage compounds and regulatory affairs.